My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
March 2016
PATIENT CARE AND SCIENCE
HCV Guidance Website Updated to Reflect Latest Drug Developments
HCVguidelines.org, the website developed by IDSA and the American Association for the Study of Liver Diseases (AASLD) to provide up-to-date guidance on the treatment of hepatitis C (HCV), has released updates on several sections of the website based on newly available therapies and data. 
 
The latest release of the guidance reflects several important developments, including the recent approval of the second single-tablet fixed dose combination regimen (elbasvir/grazoprevir) for the treatment of HCV. Based on the approval of this regimen, the website now also includes guidance on the role of testing for resistance to some HCV medications that may exist in patients prior to starting therapy.  
 
While most sections of the guidance have been updated, the most significant changes have been made in the Initial Treatment of HCV Infection and Retreatment of Persons in Whom Prior Treatment Has Failed sections as well as the Unique Populations sections, which include patients living with HIV, kidney disease, and severe liver disease including those with severe liver dysfunction and those who have had a liver transplant. Updated references have been provided throughout the guidance.
 
Visit www.HCVguidelines.org for updates regarding the release of this and other sections of the guidance.
 


< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
Infections Associated with Heater-Cooler Devices
HCV Guidance Website Updated to Reflect Latest Drug Developments
HIVMA Joins Leading Health and Healthcare Organizations in Choosing Wisely® Campaign
PRACTICE MANAGEMENT
What’s Facing ID Specialists in the Health Care Payment Reform Landscape?
Deadline Extended to Avoid 2017 Medicare EHR Incentive Program Payment Penalties
Changes to CMS Sepsis Quality Measure Based on IDSA Input
Hepatitis C Treatment Access Resources for Providers
IDSA, HIVMA Join in Development of Core Quality Measures
POLICY AND ADVOCACY
Take 3 Minutes to Support Legislative Proposal to Appropriately Value ID Services
IDSA Supports Senate Committee Effort to Address CRE Outbreaks from Duodenoscopes
IDSA Comments on NSABB Draft Recommendations on Gain-of-Function Research
GLOBAL ID
Science Speaks
EDUCATION AND RESOURCES
ABIM Updates
Free Hepatitis C Module and Other MOC Resources
YOU AND YOUR COLLEAGUES
Apply Now for IDSA Fellow Advancement
Nominate Your Colleague for an IDSA or HIVMA Award
Member Report
FROM THE PRESIDENT
Zika: Working Together as Specialists and a Society to End an Outbreak
TOP STORIES
What Comes to Mind When You Hear of New Orleans in October? Think IDWeek!
Call for Committee Volunteers!
President’s Budget Request for FY 2017 is Out: What it Holds for ID and HIV
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.